Movement Alert｜HANSOH PHARMA Rises 3.34% in Regular Trading, Broker Upgrades Target Price Ahead of Interim Results

Market Focus

Aug 20

On August 20, HANSOH PHARMA rose 3.34% in regular trading, trading at 34.16 HKD/share, with turnover of approximately 93.29 million HKD.

On the news front, CMB International recently maintained its Buy rating on the company and raised its target price to 47.19 HKD, noting that the company's years of high-intensity R&D investment are gradually entering a harvest period. Excluding BD income, innovative drug revenue grew 30% year-over-year, with out-licensing revenue expected to normalize as a significant long-term profit contributor.

Additionally, the company is scheduled to release interim results on August 26. Last period, HANSOH PHARMA reported revenue of 15.028 billion yuan with a gross margin of 88.92%, and market expectations for continued revenue growth remain positive. The convergence of the broker upgrade and earnings anticipation supported the stock's strength.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/news/1182036716"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182036716\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182036716?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-20 09:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182036716","market":"us","top_or_hot":-1,"title":"Movement Alert｜HANSOH PHARMA Rises 3.34% in Regular Trading, Broker Upgrades Target Price Ahead of Interim Results","media":"Market Focus","content":"<p><p>On August 20, HANSOH PHARMA rose 3.34% in regular trading, trading at 34.16 HKD/share, with turnover of approximately 93.29 million HKD.</p><p>On the news front, CMB International recently maintained its Buy rating on the company and raised its target price to 47.19 HKD, noting that the company's years of high-intensity R&D investment are gradually entering a harvest period. Excluding BD income, innovative drug revenue grew 30% year-over-year, with out-licensing revenue expected to normalize as a significant long-term profit contributor.</p><p>Additionally, the company is scheduled to release interim results on August 26. Last period, HANSOH PHARMA reported revenue of 15.028 billion yuan with a gross margin of 88.92%, and market expectations for continued revenue growth remain positive. The convergence of the broker upgrade and earnings anticipation supported the stock's strength.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜HANSOH PHARMA Rises 3.34% in Regular Trading, Broker Upgrades Target Price Ahead of Interim Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜HANSOH PHARMA Rises 3.34% in Regular Trading, Broker Upgrades Target Price Ahead of Interim Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-20 09:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 20, HANSOH PHARMA rose 3.34% in regular trading, trading at 34.16 HKD/share, with turnover of approximately 93.29 million HKD.</p><p>On the news front, CMB International recently maintained its Buy rating on the company and raised its target price to 47.19 HKD, noting that the company's years of high-intensity R&D investment are gradually entering a harvest period. Excluding BD income, innovative drug revenue grew 30% year-over-year, with out-licensing revenue expected to normalize as a significant long-term profit contributor.</p><p>Additionally, the company is scheduled to release interim results on August 26. Last period, HANSOH PHARMA reported revenue of 15.028 billion yuan with a gross margin of 88.92%, and market expectations for continued revenue growth remain positive. The convergence of the broker upgrade and earnings anticipation supported the stock's strength.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1182036716","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182036716","pubTimestamp":1787190616,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 20, HANSOH PHARMA rose 3.34% in regular trading, trading at 34.16 HKD/share, with turnover of approximately 93.29 million HKD.On the news front, CMB International recently maintained its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"走势警报|豪森制药常规交易上涨 3.34%，经纪商在中期业绩公布前上调目标价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"On August 20, HANSOH PHARMA rose 3.34% in regular trading, trading at 34.16 HKD/share, with turnover of approximately 93.29 million HKD.On the news front, CMB International recently maintained its Buy rating on the company and raised its target price to 47.19 HKD, noting that the company's years of high-intensity R&D investment are gradually entering a harvest period. Excluding BD income, innovative drug revenue grew 30% year-over-year, with out-licensing revenue expected to normalize as a significant long-term profit contributor.Additionally, the company is scheduled to release interim results on August 26. Last period, HANSOH PHARMA reported revenue of 15.028 billion yuan with a gross margin of 88.92%, and market expectations for continued revenue growth remain positive. The convergence of the broker upgrade and earnings anticipation supported the stock's strength.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}